1
|
Zuo C, Zhang Y, Cao C, Feng J, Jiao M, Chen L. Elucidating tumor heterogeneity from spatially resolved transcriptomics data by multi-view graph collaborative learning. Nat Commun 2022; 13:5962. [PMID: 36216831 PMCID: PMC9551038 DOI: 10.1038/s41467-022-33619-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2022] [Accepted: 09/26/2022] [Indexed: 12/02/2022] Open
Abstract
Spatially resolved transcriptomics (SRT) technology enables us to gain novel insights into tissue architecture and cell development, especially in tumors. However, lacking computational exploitation of biological contexts and multi-view features severely hinders the elucidation of tissue heterogeneity. Here, we propose stMVC, a multi-view graph collaborative-learning model that integrates histology, gene expression, spatial location, and biological contexts in analyzing SRT data by attention. Specifically, stMVC adopting semi-supervised graph attention autoencoder separately learns view-specific representations of histological-similarity-graph or spatial-location-graph, and then simultaneously integrates two-view graphs for robust representations through attention under semi-supervision of biological contexts. stMVC outperforms other tools in detecting tissue structure, inferring trajectory relationships, and denoising on benchmark slices of human cortex. Particularly, stMVC identifies disease-related cell-states and their transition cell-states in breast cancer study, which are further validated by the functional and survival analysis of independent clinical data. Those results demonstrate clinical and prognostic applications from SRT data.
Collapse
Affiliation(s)
- Chunman Zuo
- Institute of Artificial Intelligence, Donghua University, Shanghai, 201620, China.
- Key Laboratory of Systems Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, 200031, China.
| | - Yijian Zhang
- Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China
| | - Chen Cao
- School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, 211166, China
| | - Jinwang Feng
- Key Laboratory of Information Fusion Technology of Ministry of Education, School of Automation, Northwestern Polytechnical University, Xi'an, 710072, China
| | - Mingqi Jiao
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, 310024, China
| | - Luonan Chen
- Key Laboratory of Systems Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, 200031, China.
- Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, 310024, China.
- Guangdong Institute of Intelligence Science and Technology, Hengqin, Zhuhai, Guangdong, 519031, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
| |
Collapse
|
2
|
Liu L, Li M, Zhang C, Zhang J, Li G, Zhang Z, He X, Fan M. Prognostic value and clinicopathologic significance of nm23 in various cancers: A systematic review and meta-analysis. Int J Surg 2018; 60:257-265. [PMID: 30389538 DOI: 10.1016/j.ijsu.2018.10.035] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2018] [Revised: 09/10/2018] [Accepted: 10/23/2018] [Indexed: 01/30/2023]
Abstract
OBJECTIVE Extensive studies have been carried out to investigate the association between nm23 expression and the prognosis and clinicopathologic significance of various tumors. METHODS AND MATERIALS Eligible studies were searched from Embase, China National Knowledge Infrastructure (CNKI), PubMed and Web of Science up to May 2017. In this study, we calculated the pooled hazard ratios (HRs) with 95% confidence intervals (95%CIs) to determine the association between nm23 expression and the prognosis of various tumors. RESULTS A total of 49 studies were finally included in the meta-analysis. The pooled HRs were 2.00 (95% CIs: 1.44-2.78) for overall survival (OS), 1.23 (95% CIs: 1.04-1.46) for disease-specific survival or progression-free survival (DFS/PFS), and 2.21 (95% CIs: 1.38-3.57) for survival of recurrence-free survival or metastasis-free survival (RFS/MFS). Moreover, the results indicated that low nm23 expression was significantly correlated with the lymph node metastasis (P = 0.002). For the subgroup analysis, the expression of nm23 in patients at N0 stage was obviously higher than the patients with breast carcinoma at N1-N3 stage [Odds ratio (OR) = 2.07, 95%CI (1.31, 3.26), P = 0.002]. Moreover, the expression of nm23 in the patients at N0 stage was remarkably higher than those at N1-N3 stages in the Chinese patients with breast carcinoma and those with nasopharyngeal carcinoma (P < 0.05). Whereas, no statistical difference was noticed in the expression of nm23 in patients of various age, gender, T stage, histological degree, TNM stage, respectively (P > 0.05). CONCLUSION Our study suggests that down-regulation of nm23 is related to poor prognosis in many cancers. The expression of nm23 in cancer tissues may serve as an important factor for evaluating the presence of lymph node metastasis.
Collapse
Affiliation(s)
- Liang Liu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China
| | - Man Li
- Department of Otolaryngology-Head and Neck Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, PR China
| | - Chengdong Zhang
- School of Life Sciences, Fudan University, Shanghai, 200082, PR China
| | - Junhua Zhang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China
| | - Guoyi Li
- Department of Otolaryngology-Head and Neck Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, PR China
| | - Zhimin Zhang
- Department of Otolaryngology-Head and Neck Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, PR China
| | - Xinhong He
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China; Department of Interventional Radiology, Shanghai Cancer Center, Fudan University, 200032, PR China.
| | - Min Fan
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, PR China.
| |
Collapse
|
3
|
Fang J, Guo X, Zheng B, Han W, Chen X, Zhu J, Xie B, Liu J, Luan X, Yan Y, He Z, Li H, Qiao C, Yu J. Correlation between NM23 protein overexpression and prognostic value and clinicopathologic features of ovarian cancer: a meta-analysis. Arch Gynecol Obstet 2017; 297:449-458. [PMID: 29274004 DOI: 10.1007/s00404-017-4620-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Accepted: 11/22/2017] [Indexed: 01/11/2023]
Abstract
OBJECTIVE The prognostic value and clinicopathological features of NM23 (non-metastasis 23) have previously been assessed, but the results are controversial. Here, we attempted to clarify the correlation between NM23 expression and its prognostic value and the clinicopathological features in ovarian cancer (OC). METHODS The relevant studies were identified using PubMed, Embase, and Web of Science. We calculated the pooled odds ratio (OR) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS), and clinicopathological features. We used OS to evaluate the prognostic value of NM23 expression in patients with OC. Subgroup analyses were used to explore the source of heterogeneity. RESULTS We included 10 studies involving 894 patients in our assessment of the association between NM23 expression and OS for OC. Our data indicated that NM23 expression was not associated with improved OS (OR 0.83, 95% CI 0.41-1.68, P = 0.61) or PFS (OR 0.7, 95% CI 0.39-1.24, P = 0.22). Elevated NM23 expression was associated with differentiation grade (OR 0.35, 95% CI 0.2-0.6, P = 0.0002) and N status (OR 0.33, 95% CI 0.14-0.78, P = 0.01), whereas there was no significant difference between NM23 expression and tumor stage (OR 1.1, 95% CI 0.45-2.66, P = 0.84). Subgroup analysis did not reveal any potential source of heterogeneity. No obvious publication bias was found. CONCLUSIONS In OC, there is poor statistical significance between NM23 expression and OS and PFS, but NM23 expression is related to differentiation grade and N status. This meta-analysis reveals that NM23 expression is a potential factor of poor prognosis in OC. The prognostic role of NM23 in different OC stages in combination with the clinical characteristics suggests a novel approach for developing future therapeutic targets.
Collapse
Affiliation(s)
- Jie Fang
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China.
| | - Xueke Guo
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China
| | - Bo Zheng
- Center for Reproduction and Genetics, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, 215002, People's Republic of China
| | - Wei Han
- Department of General Surgery, The First People's Hospital of Kunshan, Jiangsu University Affiliated Kunshan Hospital, Kunshan, 215300, Jiangsu, People's Republic of China
| | - Xia Chen
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China
| | - Jiawei Zhu
- Center for Reproduction and Genetics, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, 215002, People's Republic of China
| | - Bing Xie
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China
- Department of Obstetrics and Gynecology, The Fourth People's Hospital of Zhenjiang, Zhenjiang, 212013, Jiangsu, People's Republic of China
| | - Jiajia Liu
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China
| | - Xiaojin Luan
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China
| | - Yidan Yan
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China
| | - Zeyu He
- Department of Clinical Medicine, China Medical University, Shenyang, 110001, Liaoning, People's Republic of China
| | - Hong Li
- Center for Reproduction and Genetics, Suzhou Municipal Hospital, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, 215002, People's Republic of China
| | - Chen Qiao
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China.
- Department of Clinical Pharmacy, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China.
| | - Jun Yu
- Department of Obstetrics and Gynecology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China.
- Institute of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, People's Republic of China.
| |
Collapse
|
4
|
Han W, Ma J, Cao F, Zhang C, Zhu R, Hu YW, Chen MB, Ding HZ. The role of NM23 in patients with colorectal cancer: A systematic review and meta-analysis. ACTA ACUST UNITED AC 2017; 37:1-10. [PMID: 28224416 DOI: 10.1007/s11596-017-1686-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 11/16/2016] [Indexed: 01/11/2023]
Abstract
This meta-analysis was carried out to evaluate the relationship between NM23 expression and the prognosis of patients with colorectal cancer. We searched PubMed, EMBASE and Web of Science for relevant articles. The pooled odd ratios (ORs) and corresponding 95%CI were calculated to evaluate the prognostic value of NM23 expression in patients with colorectal cancer, and the association between NM23 expression and clinicopathological factors. In total, 2289 patients were pooled from 24 available studies. The incorporative OR combined by 16 studies with overall survival showed that high NM23 expression was associated with better overall survival (OR=0.67, 95%CI: 0.49-0.93, P=0.02, I 2=56%, Ph=0.004). And a new estimate without heterogeneity was produced when only combining high-quality studies (OR=0.70, 95%CI: 0.56-0.86, P=0.0007, I 2=46%). In disease free survival (DFS), we also obtained a good prognosis (OR=0.30, 95%CI: 0.14-0.68, P=0.004). Although we failed to find any significance in N status (P=0.10), elevated NM23 expression was related to well tumor differentiation (OR=0.60, 95%CI: 0.44-0.820, P=0.001) and Dukes' A&B (OR=0.55, 95%CI: 0.32-0.95, P=0.03). These results indicated that over-expressed NM23 might be an indicator of good prognosis, well tumor differentiation and Dukes' A&B of patients with colorectal cancer, but no significance was found in N status.
Collapse
Affiliation(s)
- Wei Han
- Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China
| | - Jun Ma
- Department of Urinary Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, 215300, China
| | - Fang Cao
- Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China
| | - Cong Zhang
- Department of Urinary Surgery, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, 215300, China
| | - Rong Zhu
- Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China
| | - Yong-Wei Hu
- Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China
| | - Min-Bin Chen
- Department of Radiotherapy and Oncology, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China
| | - Hou-Zhong Ding
- Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, 215300, China.
| |
Collapse
|
5
|
Shao WY, Yang YL, Yan H, Huang Q, Liu KJ, Zhang S. Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway. Cancer Biol Ther 2017; 18:26-35. [PMID: 27981892 PMCID: PMC5323014 DOI: 10.1080/15384047.2016.1264540] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 09/03/2016] [Accepted: 11/20/2016] [Indexed: 02/05/2023] Open
Abstract
Epithelial ovarian cancer is prone to metastasizing at an early stage, but their mechanisms remain unclear. CRM1 is an important nuclear exportin and inhibitors targeting CRM1 has been explored as an anti-cancer strategy. In previous study, we observed that PEITC could combine with the hydrophobic pocket of CRM1. In this study, we focused on the effects of PEITC on EOC and its mechanisms. Results showed that IC50 values of PEITC on SKOV3 and HO8910 cell line were 42.14 μM and 37.29 μM, respectively. PEITC inhibits the migration and invasion of SKOV3 and HO8910 cells in vitro. Oral administration of 10 μmol PEITC suppressed the metastasis of EOC in a xenograft mouse model in vivo. PEITC treatment decreased the expressions of CRM1 and mTOR (cargo protein of CRM1) in EOC cell lines and in xenograft mouse tissues. Moreover, CRM1-mediated nuclear export was attenuated by PEITC, mTOR accumulated in nucleus, expressions of mTORS2448 and downstream effectors STAT3S727, MMP2 and MMP9 were decreased in a dose- and time-dependent manner. Furthermore, immunohistochemical analysis showed that CRM1 and mTOR were increased in EOC tissues compared with benign ovarian tumors, and related with advanced stage, type II EOC, positive peritoneal cytology and decreased overall survival. In addition, CRM1 was positively correlated with mTOR levels. In conclusion, our data demonstrated that PEITC suppresses the metastasis of EOC through inhibiting CRM1-mediated nuclear export, subsequently suppressing the mTOR-STAT3 pathway. Both CRM1 and mTOR were increased in EOC patients, providing a rationale for further clinical investigation of PEITC in EOC treatment.
Collapse
Affiliation(s)
- Wen Yu Shao
- Department of Gynecological Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
| | - Yong Liang Yang
- School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China
| | - Huan Yan
- Department of Obstetrics and Gynecology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China
| | - Qian Huang
- Department of Gynecological Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China
| | - Kai Jiang Liu
- Department of Gynecological Oncology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
| | - Shu Zhang
- Department of Obstetrics and Gynecology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China
| |
Collapse
|
6
|
Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew KP, Wu YL, Zhang S. MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget 2015; 5:12291-303. [PMID: 25460499 PMCID: PMC4323008 DOI: 10.18632/oncotarget.2577] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2014] [Accepted: 10/06/2014] [Indexed: 12/19/2022] Open
Abstract
Metastasis is major cause of mortality in patients with ovarian cancer. MiR-373 has been shown to play pivotal roles in tumorigenesis and metastasis; however, a role for miR-373 in ovarian cancer has not been investigated. In this study, we show that the miR-373 expression is down-regulated in human epithelial ovarian cancer (EOC) and inversely correlated with clinical stage and histological grade. Ectopic overexpression of miR-373 in human EOC cells suppressed cell invasion in vitro and metastasis in vivo, and the epithelial–mesenchymal transition process. Silencing the expression of miR-373 resulted in an increased migration and invasion of EOC cells. Using integrated bioinformatics analysis, gene expression arrays, and luciferase assay, we identified Rab22a as a direct and functional target of miR-373 in EOC cells. Expression levels of miR-373 were inversely correlated with Rab22a protein levels in human EOC tissues. Rab22a knockdown inhibited invasion and migration of EOC cells, increased E-cadherin expression, and suppressed the expression of N-cadherin. Moreover, overexpression of Rab22a abrogated miR-373-induced invasion and migration of EOC cells. Taken together, these results demonstrate that miR-373 suppresses EOC invasion and metastasis by directly targeting Rab22a gene, a new potential therapeutic target in EOC.
Collapse
Affiliation(s)
- Yue Zhang
- Department of Obstetrics and Gynecology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China
| | - Fu-Jun Zhao
- Department of Urology, Shanghai First People's Hospital, Shanghai Jiao-Tong University, Shanghai, 200080, China
| | - Li-Lan Chen
- Department of Obstetrics and Gynecology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China
| | - Luo-Qiao Wang
- Department of Obstetrics and Gynecology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China
| | - Kenneth P Nephew
- Medical Sciences, Indiana University School of Medicine, Bloomington, IN 47405, USA
| | - Ying-Li Wu
- Department of Pathophysiology, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Shanghai Jiao-Tong University School of Medicine, Shanghai, 200025, China
| | - Shu Zhang
- Department of Obstetrics and Gynecology, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, China
| |
Collapse
|
7
|
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A 2014; 112:232-7. [PMID: 25535366 DOI: 10.1073/pnas.1422165112] [Citation(s) in RCA: 120] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
High-grade serous ovarian carcinoma (HGSOC) is the most common and aggressive form of epithelial ovarian cancer, for which few targeted therapies exist. To search for new therapeutic target proteins, we performed an in vivo shRNA screen using an established human HGSOC cell line growing either subcutaneously or intraperitoneally in immunocompromised mice. We identified genes previously implicated in ovarian cancer such as AURKA1, ERBB3, CDK2, and mTOR, as well as several novel candidates including BRD4, VRK1, and GALK2. We confirmed, using both genetic and pharmacologic approaches, that the activity of BRD4, an epigenetic transcription modulator, is necessary for proliferation/survival of both an established human ovarian cancer cell line (OVCAR8) and a subset of primary serous ovarian cancer cell strains (DFs). Among the DFs tested, the strains sensitive to BRD4 inhibition revealed elevated expression of either MYCN or c-MYC, with MYCN expression correlating closely with JQ1 sensitivity. Accordingly, primary human xenografts derived from high-MYCN or c-MYC strains exhibited sensitivity to BRD4 inhibition. These data suggest that BRD4 inhibition represents a new therapeutic approach for MYC-overexpressing HGSOCs.
Collapse
|
8
|
Mechanisms of ovarian cancer metastasis: biochemical pathways. Int J Mol Sci 2012; 13:11705-11717. [PMID: 23109879 PMCID: PMC3472771 DOI: 10.3390/ijms130911705] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Revised: 08/31/2012] [Accepted: 09/03/2012] [Indexed: 12/18/2022] Open
Abstract
Ovarian cancer is the most lethal gynecologic malignancy. Despite advances in chemotherapy, the five-year survival rate of advanced ovarian cancer patients with peritoneal metastasis remains around 30%. The most significant prognostic factor is stage, and most patients present at an advanced stage with peritoneal dissemination. There is often no clearly identifiable precursor lesion; therefore, the events leading to metastatic disease are poorly understood. This article reviews metastatic suppressor genes, the epithelial-mesenchymal transition (EMT), and the tumor microenvironment as they relate to ovarian cancer metastasis. Additionally, novel chemotherapeutic agents targeting the metastasis-related biochemical pathways are discussed.
Collapse
|
9
|
Li Y, Kang S, Qin JJ, Wang N, Zhou RM, Sun HY. nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease. Gynecol Oncol 2012; 126:455-9. [PMID: 22683585 DOI: 10.1016/j.ygyno.2012.06.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Revised: 05/31/2012] [Accepted: 06/04/2012] [Indexed: 11/30/2022]
Abstract
OBJECTIVE nm23, a tumor metastasis suppressor gene, has been linked to protection against tumorigenesis and tumor metastasis. This study evaluated whether genetic variants in the nm23 gene were associated with susceptibility to epithelial ovarian cancer (EOC) or the clinical outcome of patients. METHODS A case-control study was performed with 302 patients with epithelial ovarian cancer and 302 control women. According to the genotypes, the outcome in 213 EOC patients was compared. Progression-free survival (PFS) and overall survival (OS) were analyzed with Kaplan-Meier plots and Cox models adjusted for clinical factors. RESULTS The case-control analysis showed that the rs16949649 and rs2302254 polymorphisms in the nm23 gene promoter were not associated with the risk of developing EOC. In contrast, survival analysis showed that the rs2302254 C/T polymorphism was related to the prognosis of EOC patients. Compared with patients carrying the C/C genotype, patients carrying the T/T genotype had a shorter median PFS and median OS by Kaplan-Meier plots and Cox models adjusted for clinical factors. For rs16949649 T/C polymorphisms, Kaplan-Meier analysis indicated that patients carrying the homozygous C/C genotype had shorter PFS and OS than those carrying the T allele (T/T+T/C genotype). The Cox proportional hazard model analysis suggested that this relationship was only retained in OS when adjusted for clinical factors. CONCLUSION Our studies suggest that rs16949649 and rs2302254 polymorphisms in the nm23 gene promoter may influence the prognosis of patients with epithelial ovarian cancer.
Collapse
Affiliation(s)
- Yan Li
- Department of Molecular Biology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China.
| | | | | | | | | | | |
Collapse
|
10
|
Khadjavi A, Barbero G, Destefanis P, Mandili G, Giribaldi G, Mannu F, Pantaleo A, Ceruti C, Bosio A, Rolle L, Turrini F, Fontana D. Evidence of Abnormal Tyrosine Phosphorylated Proteins in the Urine of Patients With Bladder Cancer: The Road Toward a New Diagnostic Tool? J Urol 2011; 185:1922-9. [DOI: 10.1016/j.juro.2010.12.029] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2010] [Indexed: 10/18/2022]
Affiliation(s)
- Amina Khadjavi
- Research Center for Experimental Medicine, University of Turin Medical School, Turin, Italy
- Department of Genetics, Biology and Biochemistry, University of Turin Medical School, Turin, Italy
- DIAPHAN Consortium, University of Turin Medical School, Turin, Italy
| | - Giovanna Barbero
- Department of Genetics, Biology and Biochemistry, University of Turin Medical School, Turin, Italy
| | - Paolo Destefanis
- Divisione Universitaria di Urologia 2-Ospedale San Giovanni Battista Molinette, University of Turin Medical School, Turin, Italy
| | - Giorgia Mandili
- Research Center for Experimental Medicine, University of Turin Medical School, Turin, Italy
- Department of Genetics, Biology and Biochemistry, University of Turin Medical School, Turin, Italy
| | - Giuliana Giribaldi
- Department of Genetics, Biology and Biochemistry, University of Turin Medical School, Turin, Italy
- DIAPHAN Consortium, University of Turin Medical School, Turin, Italy
| | - Franca Mannu
- DIAPHAN Consortium, University of Turin Medical School, Turin, Italy
- Nurex S. R. L., Sassari, Italy
| | | | - Carlo Ceruti
- Divisione Universitaria di Urologia 2-Ospedale San Giovanni Battista Molinette, University of Turin Medical School, Turin, Italy
| | - Andrea Bosio
- Divisione Universitaria di Urologia 2-Ospedale San Giovanni Battista Molinette, University of Turin Medical School, Turin, Italy
| | - Luigi Rolle
- Divisione Universitaria di Urologia 2-Ospedale San Giovanni Battista Molinette, University of Turin Medical School, Turin, Italy
| | - Francesco Turrini
- Research Center for Experimental Medicine, University of Turin Medical School, Turin, Italy
- DIAPHAN Consortium, University of Turin Medical School, Turin, Italy
| | - Dario Fontana
- DIAPHAN Consortium, University of Turin Medical School, Turin, Italy
- Divisione Universitaria di Urologia 2-Ospedale San Giovanni Battista Molinette, University of Turin Medical School, Turin, Italy
| |
Collapse
|
11
|
Abstract
Over the past 25 years, an expanding set of metastasis-suppressor genes (MSGs) has been identified that specifically regulate metastasis formation without affecting primary growth. MSGs are involved in diverse molecular processes in multiple tumor types. Given the wealth of metastasis biology that underlies their functions, treatment strategies based on MSGs have an unparalleled potential to improve patient care. Using NM23 as a prime example, we discuss how specific MSGs have been used as prognostic markers, tools for predicting response to treatment, and targets for the development of novel therapies. Barriers specific to the translation of MSG biology into clinical practice are reviewed and future research directions necessary for clinical advances are delineated. Although to date the impact of MSGs on patient care is limited, it is an expanding field with vast potential to help develop new treatments and identify patients who will most benefit from them.
Collapse
|
12
|
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia 2011; 12:993-1002. [PMID: 21170264 DOI: 10.1593/neo.101044] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2010] [Revised: 09/06/2010] [Accepted: 09/09/2010] [Indexed: 01/13/2023] Open
Abstract
Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the fallopian tube of BRCA1 mutation carriers at the time of risk-reducing salpingo-oophorectomy, suggesting that many BRCA1-mutated ovarian carcinomas originate in tubal epithelium. We hypothesized that changes in gene expression profiles within the histologically normal fallopian tube epithelium of BRCA1 mutation carriers would overlap with the expression profiles in BRCA1-mutated ovarian carcinomas and represent a BRCA1 preneoplastic signature. Laser capture microdissection of frozen sections was used to isolate neoplastic cells or histologically normal fallopian tube epithelium, and expression profiles were generated on Affymetrix U133 Plus 2.0 gene expression arrays. Normal-risk controls were 11 women wild type for BRCA1 and BRCA2 (WT-FT). WT-FT were compared with histologically normal fallopian tube epithelium from seven women with deleterious BRCA1 mutations who had foci of at least intraepithelial neoplasm within their fallopian tube (B1-FTocc). WT-FT samples were also compared with 12 BRCA1 ovarian carcinomas (B1-CA). The comparison of WT-FT versus B1-FTocc resulted in 152 differentially expressed probe sets, and the comparison of WT-FT versus B1-CA resulted in 4079 differentially expressed probe sets. The BRCA1 preneoplastic signature was composed of the overlap between these two lists, which included 41 concordant probe sets. Genes in the BRCA1 preneoplastic signature included several known tumor suppressor genes such as CDKN1C and EFEMP1 and several thought to be important in invasion and metastasis such as E2F3. The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry.
Collapse
|
13
|
Gao J, Gao G, Zhang Y, Wang F. Proteomic analysis of human epithelial ovarian cancer xenografts in immunodeficient mice exposed to chronic psychological stress. SCIENCE CHINA-LIFE SCIENCES 2011; 54:112-20. [DOI: 10.1007/s11427-010-4126-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2010] [Accepted: 10/13/2010] [Indexed: 01/23/2023]
|
14
|
Yang Z, Qu LJ, Wu YM, Zeng L, Xiong XS. Significance of DR-nm23 protein expression in colorectal carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18:1563-1568. [DOI: 10.11569/wcjd.v18.i15.1563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the relationship between the expression of DR-nm23 protein and the carcinogenesis, progression and metastasis of colorectal carcinoma.
METHODS: Ninety-eight colorectal carcinoma specimens, 57 adenoma specimens and 42 normal colorectal tissue specimens were examined by immunohistochemistry using the streptavidin-peroxidase method. The correlation of DR-nm23 protein expression with the carcinogenesis, progression, lymph node metastasis, histological type and differentiation grade of colorectal carcinoma was then analyzed.
RESULTS: The positive rate of DR-nm23 protein expression was significantly higher in normal colorectal tissue than in adenoma and colorectal carcinoma (71.4% vs 38.6% and 35.7%, respectively; both P < 0.01). The positive rate of DR-nm23 protein expression was significantly lower in high-grade intraepithelial tumors than in low-grade intraepithelial tumors in the adenoma group (25.7% vs 59.1%, P < 0.05), and in metastatic colorectal carcinoma than in non-metastatic colorectal carcinoma (23.1% vs 44.1%, P < 0.05). The expression of DR-nm23 is negatively related to lymph node metastasis (P < 0.05). DR-nm23 expression is also closely related to histological type (χ2 = 13.731, P < 0.01) and differentiation grade (χ2 = 12.198, P < 0.01). The positive rate of DR-nm23 protein was higher in secondary tumors than in primary tumors in the metastatic colorectal carcinoma group though no significant difference was noted between them (P > 0.05).
CONCLUSION: Decreased DR-nm23 protein expression is closely related to tumor differentiation, carcinogenesis, progression and metastasis in colorectal carcinoma. DR-nm23 is an important parameter for evaluation of the biological behavior and prognosis of colorectal carcinoma.
Collapse
|
15
|
Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 2008; 65:41-8. [PMID: 19058872 DOI: 10.1016/j.lungcan.2008.10.024] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2008] [Revised: 10/13/2008] [Accepted: 10/14/2008] [Indexed: 01/21/2023]
Abstract
A quantitative proteomic approach was used to discover potential protein markers associated with lymph node metastasis (LNM) in human lung squamous carcinoma (LSC). Laser capture microdissection was performed to purify LSC cells with LNM (LNM LSC) and LSC without LNM (non-LNM LSC). The differentially expressed proteins between pooled microdissected non-LNM LSC and LNM LSC cells were identified by two-dimensional difference gel electrophoresis (2D-DIGE) coupled with mass spectrometry (MS). 14 proteins were found to be differentially expressed between non-LNM LSC and LNM LSC. Among these proteins, ten proteins were overexpressed in LNM LSC compared with non-LNM LSC, and four proteins were downregulated in LNM LSC. Some of these identified proteins (Annexin A2, HSP27, CK19, and 14-3-3sigma) were further confirmed by Western blotting and immunohistochemical analysis. These results show the value of LCM coupled with 2D-DIGE in identifying potential markers for lymph node metastasis of LSC, and also provide further insights into the prognosis of LSC.
Collapse
|